We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+2.67%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$770M
AUM Growth
-$93.1M
Cap. Flow
-$86.4M
Cap. Flow %
-11.23%
Top 10 Hldgs %
76.77%
Holding
47
New
8
Increased
7
Reduced
11
Closed
2

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$36.6M
2
PTCT icon
PTC Therapeutics
PTCT
+$8.85M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$8.77M
4
EW icon
Edwards Lifesciences
EW
+$2.87M
5
BNTX icon
BioNTech
BNTX
+$2.32M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$28.3M
2
RVNC
Revance Therapeutics, Inc.
RVNC
+$18.1M
3
INSM icon
Insmed
INSM
+$14.6M
4
BIIB icon
Biogen
BIIB
+$12.6M
5
STAA icon
STAAR Surgical
STAA
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.76%
2 Financials 1.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$29B
$142M 18.4%
1,940,993
-197,970
-9% -$14.6M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$87M 11.3%
8,145,311
-884,532
-10% -$9.63M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$13.5B
$76.6M 9.95%
1,090,056
-40,111
-4% -$3.35M
UTHR icon
4
United Therapeutics
UTHR
$22.1B
$65.7M 8.53%
183,246
-83,668
-31% -$28.3M
BIIB icon
5
Biogen
BIIB
$30.1B
$44.4M 5.76%
228,916
-60,134
-21% -$12.6M
STAA icon
6
STAAR Surgical
STAA
$1.24B
$40.6M 5.27%
1,091,608
-290,011
-21% -$10.8M
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$5.07B
$38.8M 5.04%
2,523,956
+105,115
+4% +$1.75M
ALNY icon
8
Alnylam Pharmaceuticals
ALNY
$29.6B
$38.7M 5.03%
+140,681
New +$36.6M
PRTA icon
9
Prothena Corp
PRTA
$473M
$29.1M 3.78%
1,737,964
+71,586
+4% +$1.54M
IOVA icon
10
Iovance Biotherapeutics
IOVA
$2.94B
$28.6M 3.71%
3,041,685
+925,282
+44% +$8.77M
ANAB icon
11
AnaptysBio
ANAB
$1.71B
$28.3M 3.67%
843,971
+40,330
+5% +$1.38M
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.92B
$26.3M 3.41%
210,258
+8,575
+4% +$1.19M
ALKS icon
13
Alkermes
ALKS
$8.26B
$10.8M 1.4%
384,656
-110,936
-22% -$2.96M
PTCT icon
14
PTC Therapeutics
PTCT
$6.15B
$9.81M 1.27%
+264,469
New +$8.85M
ALGN icon
15
Align Technology
ALGN
$12.3B
$9.61M 1.25%
37,772
– –
EHTH icon
16
eHealth
EHTH
$39.1M
$9.58M 1.24%
2,347,519
-2,671
-0.1% -$11.5K
NVCR icon
17
NovoCure
NVCR
$2.06B
$9.28M 1.21%
593,540
+31,632
+6% +$574K
SLRN
18
DELISTED
ACELYRIN
SLRN
$8.84M 1.15%
1,792,895
+77,715
+5% +$401K
RVNC
19
DELISTED
Revance Therapeutics, Inc.
RVNC
$8.37M 1.09%
1,611,787
-3,645,299
-69% -$18.1M
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.81B
$7.8M 1.01%
405,193
– –
SAGE
21
DELISTED
Sage Therapeutics
SAGE
$7.3M 0.95%
1,010,833
– –
GOSS icon
22
Gossamer Bio
GOSS
$88.9M
$6.19M 0.8%
6,277,093
– –
KPTI icon
23
Karyopharm Therapeutics
KPTI
$47.6M
$4.23M 0.55%
340,146
– –
NVRO
24
DELISTED
NEVRO CORP.
NVRO
$4.19M 0.54%
750,371
– –
BNTX icon
25
BioNTech
BNTX
$23.3B
$2.99M 0.39%
+25,206
New +$2.32M
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
RK
Rather & Kittrell Knoxville, Tennessee $648M AUM 14.68% 1-Year Est. Return

Palo Alto Investors's Q3 2024 Portfolio in Review

As of Q3 2024, Palo Alto Investors held 47 positions worth $770M, down 11% from $863M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Palo Alto Investors withdrew a net $86.4M in Q3 2024, closing 2 positions and reducing 11 holdings. Its most notable exit was Cytokinetics, an estimated $6.05M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Financials.

Against the trend, Palo Alto Investors opened a new position in Alnylam Pharmaceuticals worth $38.7M.

  • Palo Alto Investors's largest Q3 2024 buy was Alnylam Pharmaceuticals: 140,681 shares worth $38.7M.
  • Palo Alto Investors added most to Iovance Biotherapeutics in Q3 2024, an estimated $8.77M increase.
  • Palo Alto Investors's biggest Q3 2024 reduction was United Therapeutics, cutting an estimated $28.3M.
  • Palo Alto Investors fully exited Cytokinetics in Q3 2024, selling an estimated $6.05M.
  • Palo Alto Investors's ten largest holdings make up 77% of its $770M portfolio in Q3 2024.
  • Palo Alto Investors opened 8 new positions and closed 2 in Q3 2024.
  • Palo Alto Investors's portfolio value fell 11% quarter-over-quarter to $770M.

Based on Palo Alto Investors's 13F filing for Q3 2024, filed 14 Nov 2024.